Organisation paid for research Program year 2025 Source: CMS Open Payments

Revive Research Institute

Neither a doctor nor a teaching hospital

Research payments

$335,187

150 payments

Through program year 2025, Revive Research Institute is reported as receiving $335,187 in research payments, across 150 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $198,155 82
2024 Research $50,180 49
2022 Research $63,403 11
2021 Research $1,897 1
2020 Research $21,552 7

Breakdown

Who paid Research payments · program years 2020–2025
  1. C. R. Bard, Inc. & Subsidiaries $127,116 1 payment
  2. Takeda Pharmaceuticals U.S.A., Inc. $61,001 15 payments
  3. Incyte Corporation $55,588 111 payments
  4. ITI, Inc. $32,804 9 payments
  5. BioXcel Therapeutics, Inc. $21,750 3 payments
  6. Amgen Inc. $15,376 4 payments
  7. Pfizer Inc. $12,977 3 payments
  8. BeiGene, Ltd. $8,575 4 payments
Studies the money was for Research payments · program years 2020–2025
  1. Purest $127,116 1 payment
  2. A Study of Pvp001, Pvp002, and Pvp003 in Healthy Adults and Pvp001 and Pvp002 in Adults With Celiac Disease $35,924 6 payments
  3. A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma $26,870 59 payments
  4. Bxcl501401 $21,750 3 payments
  5. A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma $21,148 41 payments
  6. Iti-007-601 $17,002 5 payments
  7. Iti-007-421 $15,802 4 payments
  8. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of Tak-101 for the Prevention of Gluten-Specific T Cell Activation in Subjects With Celiac Disease on A Gluten-Free Diet $14,000 2 payments
  9. P3 3L + Vectibix vs Pi choice CRC CB 300 $13,479 3 payments
  10. A Phase 2B Multicenter Randomized Doubleblind Placebocontrolled Doseranging Study to Evaluate the Efficacy Safety and Pharmacokinetics of Pf06480605 in Adult Participants With Moderate to Severe Ulcerative Colitis $12,977 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record